Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07458906
NA

DLL3-Targeted PET/CT in Neuroendocrine Carcinoma

Sponsor: The First Affiliated Hospital of Xiamen University

View on ClinicalTrials.gov

Summary

The objective of the study is to evaluate the diagnostic value of DLL3-targeted PET/CT in patients with suspected or histologically confirmed neuroendocrine carcinoma, and to compare with conventional imaging modalities.

Official title: Delta-like Protein 3 (DLL3)- Targeted PET Imaging in Neuroendocrine Carcinoma

Key Details

Gender

All

Age Range

18 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

60

Start Date

2025-12-01

Completion Date

2026-12-31

Last Updated

2026-03-09

Healthy Volunteers

No

Interventions

DIAGNOSTIC_TEST

Diagnostic Test: conventional imaging (CT, MRI or 18F-FDG PET/CT), DLL3-targeted PET/CT

Participants will undergo DLL3-Targeted PET/CT imaging for the evaluation of tumor lesions. Imaging findings will be compared with conventional imaging modalities as part of the study analysis.

Locations (1)

The First Affiliated Hospital of Xiamen University

Xiamen, Fujian, China